ALVR vs. PLX, CVM, ATRA, ATHA, DTIL, CRIS, PASG, GRTS, CGTX, and SGMO
Should you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include Protalix BioTherapeutics (PLX), CEL-SCI (CVM), Atara Biotherapeutics (ATRA), Athira Pharma (ATHA), Precision BioSciences (DTIL), Curis (CRIS), Passage Bio (PASG), Gritstone bio (GRTS), Cognition Therapeutics (CGTX), and Sangamo Therapeutics (SGMO). These companies are all part of the "biological products, except diagnostic" industry.
Protalix BioTherapeutics (NYSE:PLX) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership, community ranking and analyst recommendations.
Protalix BioTherapeutics has a net margin of 12.69% compared to Protalix BioTherapeutics' net margin of 0.00%. AlloVir's return on equity of 29.73% beat Protalix BioTherapeutics' return on equity.
16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 5.0% of Protalix BioTherapeutics shares are owned by company insiders. Comparatively, 40.0% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, AlloVir had 7 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 8 mentions for AlloVir and 1 mentions for Protalix BioTherapeutics. AlloVir's average media sentiment score of 0.00 beat Protalix BioTherapeutics' score of -0.80 indicating that Protalix BioTherapeutics is being referred to more favorably in the media.
AlloVir received 22 more outperform votes than Protalix BioTherapeutics when rated by MarketBeat users. However, 62.50% of users gave Protalix BioTherapeutics an outperform vote while only 57.45% of users gave AlloVir an outperform vote.
Protalix BioTherapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 740.34%. AlloVir has a consensus target price of $18.67, suggesting a potential upside of 2,308.60%. Given Protalix BioTherapeutics' higher probable upside, analysts clearly believe AlloVir is more favorable than Protalix BioTherapeutics.
Protalix BioTherapeutics has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.
Protalix BioTherapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.
Summary
Protalix BioTherapeutics beats AlloVir on 11 of the 16 factors compared between the two stocks.
Get AlloVir News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
